{"prompt": "['concomitant medications will be summarized by Anatomical Therapeutic Chemical (ATC) 3', 'classification and preferred name.', 'Overall safety assessment will include evaluation of the following specific events:', 'Neurological events including: stroke, TIA, visual symptoms, migraines', 'Venous Thromboembolic Events (VTE) in the treated leg', 'Post-treatment local effects including hyperpigmentation, granuloma formation,', 'ulceration in the treated leg', 'Thrombus formation in deep veins (e.g., femoral vein) in the treated leg', 'Post-ablation superficial thrombus extension (PASTE) in the treated leg', 'Local and systemic allergic reactions, including anaphylaxis', '11.10.', 'Protocol Deviations/Violations', 'Protocol deviations will be identified prior to database lock and will be listed by treatment', 'group in the clinical study report. A protocol violation occurs when the patient, Investigator, or', 'Sponsor fails to adhere to significant protocol requirements affecting the inclusion/exclusion', 'criteria, patient safety, or primary endpoint criteria.', 'Protocol violations for this study include, but are not limited to, the following:', 'Failure to meet inclusion/exclusion criteria', 'Use of a prohibited concomitant medication', 'Failure to attend two post treatment visits: of which one is Week 12', 'Failure to comply with Good Clinical Practice (GCP) guidelines will result in a protocol', 'violation. Sponsor will determine if a protocol violation will result in withdrawal of a patient', 'from the study.', 'When a protocol violation occurs, it will be discussed with the Investigator and a Protocol', 'Violation Form detailing the violation will be generated. This form will be signed by a Sponsor', \"representative and the Investigator. A copy of the form will be filed in the site's regulatory\", \"binder and in the Sponsor's files.\", 'Page 49 of 101']['12.', 'ETHICS AND GENERAL CLINICAL TRIAL CONDUCT', 'CONSIDERATIONS', 'The study will be conducted according GCP guidelines and the applicable regulatory', 'requirements, and in accordance with the ethical standards that have their origin in the', 'Declaration of Helsinki, Protection of Human Volunteers (21 CFR 50), Institutional Review', 'Boards (21 CFR 56), and Obligations of Clinical Investigators (21 CFR 312). To ensure ethical', 'conduct of this clinical study, Investigators will be expected to adhere to the basic principles in', 'recognized guidelines such the Belmont Report and the International Ethical Guidelines for', 'Biomedical Research Involving Human Subjects.', 'To maintain confidentiality at the Investigational site, all laboratory specimens, evaluation', \"forms, reports, and other records will be identified by a coded number and patient's initials\", \"only. All study records will be kept in a locked file cabinet. Coded sheets linking a patient's\", 'name to a patient identification number will be stored in a separately locked file cabinet.', 'Clinical information will not be released without written permission of the patient, except as', 'necessary for monitoring by the FDA. The Investigator must also comply with all applicable', 'privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996, EU Data', 'Protection Directive 95/46/EC).', '12.1.', 'Institutional Review Board or Ethics Committee Approval', 'The protocol and the informed consent document must have the initial and at least annual (when', 'required) approval of an IRB/EC. The signed IRB/EC approval letter must identify the', \"documents approved (i.e., list the Investigator's name, the protocol number and title, the date of\", 'the protocol and informed consent document, and the date of approval of the protocol and the', 'informed consent document). Any advertisements used to recruit patients should also be', 'reviewed by the IRB/EC. The Sponsor will not ship clinical supplies until a signed approval', 'letter from the IRB/EC has been received and a Clinical Trial Agreement has been signed by the', 'Sponsor and the clinical site.', '12.2.', 'Informed Consent', 'Informed consent form (ICF) will be obtained in accordance with the Declaration of Helsinki,', 'ICH GCP, US Code of Federal Regulations for Protection of Human Subjects (21 CFR', '50.25[a,b], CFR 50.27, and CFR Part 56, Subpart A), the Health Insurance Portability and', 'Accountability Act (HIPAA, if applicable), and local regulations.', 'A master ICF template will be provided by VI or its representative to each investigational study', 'site. The Investigator will review and modify this document, if necessary. If any modifications', 'are made, they must be approved by VI or its representative. The Investigator will provide the', 'final informed consent form, assent, and HIPAA authorization to the Sponsor or designee for', 'approval prior to submission to the IRB/EC. The consent form generated by the Investigator', 'must be acceptable to the Sponsor and be approved by the IRB/EC. The written consent', 'document will embody the elements of informed consent as described in the International', 'Conference on Harmonization and will also comply with local regulations. The Investigator will', 'send an IRB/EC-approved copy of the Informed Consent Form to the Sponsor (or designee) for', 'Page 50 of 101']\n\n###\n\n", "completion": "END"}